{
    "Trade/Device Name(s)": [
        "Aptima SARS-CoV-2 Assay"
    ],
    "Submitter Information": "Hologic, Inc.",
    "510(k) Number": "K243396",
    "Predicate Device Reference 510(k) Number(s)": [
        "K211079"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QQX"
    ],
    "Summary Letter Date": "October 31, 2024",
    "Summary Letter Received Date": "October 31, 2024",
    "Submission Date": "February 11, 2025",
    "Regulation Number(s)": [
        "21 CFR 866.3981"
    ],
    "Regulation Name(s)": [
        "Device To Detect And Identify Nucleic Acid Targets In Respiratory Specimens From Microbial Agents That Cause The SARS-CoV-2 Respiratory Infection And Other Microbial Agents When In A Multi-Target Test"
    ],
    "Analyte Class(es)": [
        "virology",
        "microbiology"
    ],
    "Analyte(s)": [
        "SARS-CoV-2 RNA"
    ],
    "Specimen Type(s)": [
        "Nasopharyngeal swab",
        "Anterior nasal swab"
    ],
    "Specimen Container(s)": [
        "Viral Transport Media (VTM)",
        "Universal Transport Media (UTM)",
        "RespDirect Collection Kit",
        "Panther Fusion Specimen Lysis Tubes",
        "Direct Capture Tube with eSTM"
    ],
    "Instrument(s)/Platform(s)": [
        "Panther system",
        "Panther Fusion system"
    ],
    "Method(s)/Technology(ies)": [
        "Nucleic acid amplification",
        "Transcription Mediated Amplification (TMA)",
        "Dual Kinetic Assay (DKA)",
        "Target capture",
        "Chemiluminescent probe hybridization"
    ],
    "Methodologies": [
        "Molecular amplification testing",
        "Nucleic acid detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Controls",
        "Ancillary component",
        "Specimen collection device"
    ],
    "Document Summary": "FDA 510(k) summary for Aptima SARS-CoV-2 Assay using nucleic acid amplification on Panther/Panther Fusion systems for qualitative detection of SARS-CoV-2 RNA in nasopharyngeal and anterior nasal swab specimens",
    "Indications for Use Summary": "Intended for qualitative detection of SARS-CoV-2 RNA from nasopharyngeal and anterior nasal swab specimens collected from symptomatic patients as an aid in the diagnosis of COVID-19, to be used with other clinical and epidemiological information",
    "fda_folder": "Microbiology"
}